CD19 and neoplasm: When tumor cells were pre-sensitized with venetoclax prior to CD19 CAR T cell therapy, there was a significant improvement in the anti-tumor effect of the CAR T cells, as well as enhanced early expansion and long-term persistence of the CAR T cells in vitro [76].